Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02280590

Enrollment

223

Registered

2014-10-31

Start date

2014-09-30

Completion date

Unknown

Last updated

2015-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Brief summary

Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia \- 8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design

Interventions

DRUGRosuvastatin(Cresnon®)

10mg

DRUGRosuvastatin(Crestor®)

10mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 20 * Persons who have not reached LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis

Design outcomes

Primary

Measure	Time frame
The percent change in LDL-C	After taken medication for 8 weeks

Secondary

Measure	Time frame
The percent change in total cholesterol, Triglyceride, HDL-C, non-HDL-C, and non-HDL-C/HDL-C	After taken medication for 8 weeks
The proportion of subjects reaching LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis	After taken medication for 8 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026